Viroimmunotherapy for Colorectal Cancer: Clinical Studies
AbstractColorectal cancer is a leading cause of cancer incidence and death. Therapies for those with unresectable or recurrent disease are not considered curative at present. More effective and less toxic therapies are desperately needed. Historically, the immune system was thought to be an enemy to oncolytic viral therapy. Thinking that oncolysis would be the only mechanism for cell death, oncolytic virologists theorized that immune clearance was a detriment to oncolysis. Recent advances in our understanding of the tumor microenvironment, and the interplay of tumor survival and a patient’s immune system have called into question our understanding of both arenas. It remains unclear what combination of restrictions or enhancements of innate and/or cell-mediated immunity can yield the highest likelihood of viral efficacy. This article reviews the variety of mechanisms explored for viruses such as immunotherapy for colorectal cancer. View Full-Text
Share & Cite This Article
Chaurasiya, S.; Warner, S. Viroimmunotherapy for Colorectal Cancer: Clinical Studies. Biomedicines 2017, 5, 11.
Chaurasiya S, Warner S. Viroimmunotherapy for Colorectal Cancer: Clinical Studies. Biomedicines. 2017; 5(1):11.Chicago/Turabian Style
Chaurasiya, Shyambabu; Warner, Susanne. 2017. "Viroimmunotherapy for Colorectal Cancer: Clinical Studies." Biomedicines 5, no. 1: 11.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.